As early as 2004, Eustace and colleagues demonstrated that geldanamycin (GA), the prototype ATP-binding Hsp90 inhibitor, could inhibit tumor cell invasion even when chemically tethered to beads, thereby preventing its entry into cells and its interaction with intracellular Hsp90 [20]. Here, HSP90AB1 is linked to neoplasm.